MAP2K7 and non-small cell lung carcinoma: MEK inhibitors have been used in combination with PI3K and AKT inhibitors which are proximal nodes in the canonical PI3K–AKT–m-TOR pathway and such treatment regimens have shown early promise in the treatment of KRASM NSCLC (Shimizu et al, 2012; Tolcher et al, 2015b).